The promise of a simple blood test that only required a few drops of blood, but would accurately give the result of hundreds of blood test was too good to pass up on. It allowed Theranos to raise hundreds of millions of dollars and achieve a valuation of billions of dollars. Only problem: their tech doesn’t exist and never did. Now that the SEC has gotten involved, we figured we’d finally give our opinion on the whole ordeal.